Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SHR-A1307 |
Synonyms | |
Therapy Description |
SHR-A1307 is an antibody-drug conjugate that consists of an auristatin analog linked to the anti-EGFR antibody Nimotuzumab with improved half-life, which inhibits cell growth in culture and reduces tumor growth (PMID: 30962319). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SHR-A1307 | EGFR Antibody 60 | SHR-A1307 is an antibody-drug conjugate that consists of an auristatin analog linked to the anti-EGFR antibody Nimotuzumab with improved half-life, which inhibits cell growth in culture and reduces tumor growth (PMID: 30962319). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA H1047R | head and neck squamous cell carcinoma | predicted - sensitive | SHR-A1307 | Preclinical - Cell culture | Actionable | In a preclinical study, head and neck squamous cell carcinoma cells harboring PIK3CA H1047R treated with SHR-A1307 demonstrated inhibition of cell growth in culture (PMID: 30962319). | 30962319 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|